Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
Frederick J. Raal, Jean Bergeron, Daniel Gaudet, Robert S. Rosenson, David Sullivan, Traci Turner, Robert A. Hegele, Christie M. Ballantyne, Joshua W. Knowles, Nicholas J. Leeper, Ira J. Goldberg, Rong Zhou, Ma'An Muhsin, Jennifer Hellawell, James Hamilton, Gerald F. Watts
Topics & Concepts
MedicineRNA interferenceClinical trialPhase (matter)MEDLINEHydroxymethylglutaryl-CoA Reductase InhibitorsOncologyInternal medicineBioinformaticsPhases of clinical researchCancer researchPharmacologyImmunologyTherapeutic approachLipid metabolism and disordersLipoproteins and Cardiovascular HealthGrowth Hormone and Insulin-like Growth Factors